505(b)(2) formulation for schizophrenia available for in-licensing:
CHP is pleased to announce the availability
- 505(b)(2) formulation for the treatment of schizophrenia.
- Approval expected in late 2021.
- This is an oral dissolving agent. Abilify is the original molecule.
See Below for More
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png)
505(b)(2) formulation for chemotherapy available in-licensing
505(b)(2) formulation for the treatment of chemotherapy induced nausea and vomiting. Multiple advantages over currently available products including the ability to use without further reconstitution.
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png)
505(b)(2) formulation for schizophrenia available in-licensing
505(b)(2) formulation for schizophrenia available for in-licensing:
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png)
Approved 505(b)(2) available for in-licensing
Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space. US rights only.
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/In-License-icon.png)
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/In-License-icon.png)
Schizophrenia asset available for in-licensing
505(b)(2) product for the treatment of schizophrenia available for in-licensing. Multiple markets available including the US. NDA filed in the US in 2019. Approval expected in 2021.